摘要
目的:比较紫杉类和蒽环类药物联合与单纯蒽环类药物治疗三阴性乳腺癌的疗效。方法:585例三阴性乳腺癌患者中,术后行紫杉联合蒽环类辅助化疗228例,蒽环类辅助化疗357例,分析其复发、转移和生存情况。结果:紫杉联合蒽环类组与蒽环类组患者复发率、转移率与死亡率分别为7.9%与13.2%、21.9%与35.9%、18.0%与28.6%(P<0.05),与蒽环类方案相比,紫杉联合蒽环类方案延长了临床II、III期、非特殊型浸润性癌、淋巴结阳性患者的总生存期,提高了总生存率。结论:紫杉类与蒽环类药物联合辅助化疗,对于具有晚临床分期、非特殊型浸润性癌及淋巴结阳性特征的三阴性乳腺癌有显著的治疗效果。
Objective To investigate the antitumor efficacy of taxanes and antracycline drugs in triple-nega-tive breast cancer. Methods Of 585 patients with histopathologically confirmed resectable triple-negative breast cancer, 228 patients received adjuvant chemotherapy with taxanes plus antracycline, and the other 357 pa-tients received antracycline adjuvant chemotherapy. The recurrence rate, distant metastasis rate and mortality rate between two groups were analyzed. The impact of the two chemotherapy regimens on prognosis of patients in different clinical stages, pathologic types and lymph node stages was further investigated. Results The recur-rence rate, distant metastasis rate and mortality rate were 7.9% vs 13.2%, 21.9% vs 35.9% and 18.0% vs 28.6%in taxanes plus antracycline group and single antracycline group, respectively. The differences were statistically significant （P＆lt;0.05）. Taxanes plus antracycline adjuvant chemotherapy improved favorably the patients in clini-cal stages Ⅱ and Ⅲ, or the patients with a non-special invasive type or lymphatic metastasis, overall survival time and survival rate in comparison with single antracycline drug treatment group. Conclusion Compared with anthracycline regimens, the effect of taxanes combined anthracycline was more prominent in later clinical stage, non-special type invasive breast carcinoma and lymphatic metastasis triple-negative breast cancer pa-tients can improve the prognosis.
出处
《中国中西医结合外科杂志》
CAS
2014年第3期230-234,共5页
Chinese Journal of Surgery of Integrated Traditional and Western Medicine
关键词
紫杉类药
蒽环类药
三阴性乳腺癌
辅助化疗
Taxanes
antracycline
triple-negative breast cancer
adjuvant chemotherapy
